Clinical Trial Update: GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating GTI-2040 in combination with high-dose cytarabine in adults with refractory or relapsed acute myeloid leukemia, including va…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with
• Acute Myeloid Leukemia with 11q23 Abnormalities
• Acute Myeloid Leukemia with Inv

Drugs mentioned

• CYTARABINE (CYTARABINE)
• GTI-2040 (GTI-2040)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Status: COMPLETED